Abstract:Abstract Background: Thymidylate Synthetase (TYMS) is an import enzyme in the early stage of DNA biosynthesis. It is coded by the TYMS gene at 18p11.32, a region which has been found amplified in urothelial carcinoma. TYMS is a target enzyme for 5-fluorouracil (5-FU) and methotrexate. Elevated TYMS expression has been associated with poor prognosis and unfavorable therapy response in different cancer types. The aim of this study was to clarify the clinical relevance of TMYS expression in urothelial carcinoma and to determine the relationship between TYMS expression and gene amplification. Design: TYMS expression was analyzed by immunohistochemistry and TYMS copy number status was determined by fluorescence in-situ hybridization on a tissue microarray (TMA) containing more than 2,700 urothelial carcinomas of the urinary bladder including >600 patients who had undergone cystectomy for muscle-invasive disease and for which follow-up data were available. Results: TMYS immunostaining was detectable in 83.1% of 1,799 analyzable bladder cancers, including 56.4% with weak, 14.4% with moderate, and 12.3% with strong staining. The rate of strongly TMYS positive cancers increased markedly from pTaG2 low (0.3%) to pTaG2 high (4.1%), and pTaG3 cancers (11.8%; p<0.0001) and was even somewhat higher in pT2-4 cancers (16.7%; p=0.6401; pTaG3 vs pT2-4). In muscle-invasive cancers, the frequency of strong TMYS immunostaining increased with tumor stage (p=0.0011) and grade (p=0.0007) but was lower in lymph node positive cancers (p=0.0018). No association was found between TYMS expression and patient prognosis. TYMS amplification was found in 3.1% and TMYS deletion in 1.2% of 1,775 analyzable bladder cancers. The rate of TYMS amplification increased from pTa (0.6%) to pT2-4 (3.7%; p<0.0001) cancers whereas TYMS deletion was only found in pT2-4 (1.4%) cancers. In muscle invasive-cancers, TYMS copy number alterations were unrelated to tumor phenotype and patient prognosis. Strong TYMS positivity was significantly associated with TYMS amplification (p=0.0096) but only 28.6% of 42 amplified cancers showed a strong TMYS staining and only 7.2% of strongly TYMS positive cancers had a TYMS amplification. Conclusion: The significant association between TYMS overexpression and parameters of aggressive phenotype are consistent with a role of TYMS in bladder cancer progression. The incomplete association between TYMS amplification and overexpression demonstrates that TYMS is not the critical target of 18p11 amplification in bladder cancer and that TYMS upregulation is in most cases due to other mechanisms than amplification. Citation Format: Henning Plage, Sebastian Hofbauer, Kira Furlano, Sarah Weinberger, Antonia Franz, Annika Fendler, Florian Roßner, Simon Schallenberg, Sefer Elezkurtaj, Adrian Frericks, Maximilian Lennartz, Andreas H. Marx, Henrik Samtleben, Margit Fisch, Michael Rink, Marcin Slojewski, Krystian Kaczmarek, Thorsten Ecke, Stefan Koch, Nico Adamini, Ronald Simon, Guido Sauter, Henrik Zecha, Joachim Weischenfeldt, Tobias Klatte, Sarah Minner, David Horst, Thorsten Schlomm, Martina Kluth. TYMS overexpression - but not copy number alteration - is associated with cancer aggressiveness in urothelial bladder cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5131.

Abstract 4191: Thymidylate Synthase Accelerates Development of Pituitary Tumors in Men1 Knockout Mice

Thymidylate Synthase Prompts Metastatic Progression Through the Dtmp Associated EMT Process in Pancreatic Ductal Adenocarcinoma

Abstract 1439: Elucidation of the pathogenesis of prostate cancer harboring mutations of epigenetic factor UTX using genetically engineered mice

Abstract 2934: TET2 deficiency accelerates leukemogenesis in the NHD13 mouse model of MDS

Abstract 5131: TYMS overexpression - but not copy number alteration - is associated with cancer aggressiveness in urothelial bladder cancer

Abstract 6601: Menin drives oncogenesis in Ewing sarcoma cells by activating transcription of key metastatic factors

A Knock-in Mouse Model of Thymoma with the GTF2I L424H Mutation

Abstract 1047: Expression of TYMS in cancer: A tissue microarray study involving 6,613 cancers from 127 tumor entities

Abstract 1793: Transmembrane serine protease TMPRSS11B promotes tumorigenesis in lung squamous cell carcinoma through enhanced lactate export and modulation of the tumor microenvironment

Enhanced Growth of Primary Tumors in Cancer-Prone Mice after Immunization Against the Mutant Region of an Inherited Oncoprotein

Abstract 3185: Expression of DNA Methyltransferase (DNMT) Induced by Transforming Growth Factor-SS (Tgf-SS) Promotes Progress of Prostate Cancer

Abstract 5171: TP-6379, an investigational TGFBR1 inhibitor, shown to remodel the tumor microenvironment and enhance anti-tumorigenic immunological responses in syngeneic mouse models of cancer

An insight into thymidylate synthase inhibitor as anticancer agents: an explicative review

Bridging art and science with creativity support tools

Development of a novel thymidylate synthase (TS) inhibitor capable of up-regulating P53 expression and inhibiting angiogenesis in NSCLC

Abstract 6429: Critical role of elevated TMEM176B gene expression in humanized patient-derived xenografts mouse models of triple negative breast cancer

FOXM1-induced TYMS upregulation promotes the progression of hepatocellular carcinoma

Data from <i>TGFBI</i> Deficiency Predisposes Mice to Spontaneous Tumor Development

Abstract 1322: The potential effects of thymidine kinase 1 on breast cancer invasion

Abstract C010: Tumor MK2 drives tumor progression and an immunosuppressive microenvironment in head and neck squamous cell carcinoma

A 6 Bp Deletion Polymorphism in the 3’UTR of the Human Thymidylate Synthase Gene Causes Message Instability and is Associated with Decreased Intratumoral TS Mrna Levels